Can we fix the genes that cause CMT? CMTA’s Dr. Katherine Forsey breaks down the science behind genetic therapies and what’s heading toward clinical trials.
CMTA-STAR Alliance Partner Doses First CMT2S Patient
CMTA-STAR Alliance Partner Doses First CMT2S Patient
ASO Approaches for CMT2E
With CMTA support of $225,483, researchers at the University of Miami, led by CMTA Strategy...
Shift Pharmaceuticals, Charcot-Marie-Tooth Association Partner on ASO Treatment for CMT1A
CMTA has partnered with Shift Pharmaceuticals to evaluate an antisense oligonucleotide (ASO) for the treatment of CMT1A. The collaboration will use CMTA-STAR preclinical testing capabilities to assess the therapeutic potential of an ASO designed to reduce PMP22 overexpression and support advancement toward clinical trials.
